Literature DB >> 21544637

CD28 proximal promoter polymorphisms in systemic lupus erythematosus susceptibility.

Aniel Jessica Leticia Brambila-Tapia1, Ingrid P Dávalos-Rodríguez, Jorge Iván Gámez-Nava, Laura González-López, Julio Medina-Díaz, Ana Guilaisne Bernard-Medina, Mario Salazar-Páramo.   

Abstract

CD28 expression and serum levels are significantly increased in patients with SLE than in healthy controls (HC). Until now, there are no studies of proximal promoter polymorphisms of CD28 gene in SLE. Therefore, our objective was to investigate the polymorphisms present in the proximal promoter of CD28 in a group of SLE and HC and to associate the polymorphisms present with the CD28 serum levels of 40 patients and 40 controls. One hundred and seven patients as well as 108 controls matched by age range and genders were included. The 11 ACR criteria were analyzed on the clinical files, and the proximal promoter region of CD28 gene was analyzed by direct sequencing of a 489-basepair fragment. C28 serum levels (sCD28) were measured by ELISA technique in 40 patients and 40 controls. Only two of the eight reported polymorphisms were found, and they correspond to rs35593994 (-372 A/G) and rs56156157 (-145 -/C). The first had a prevalence of 41 and 36% in patients and controls respectively and the second of 1.4% in both groups. None of these polymorphisms were associated with SLE, and the polymorphism -372 A/G was not associated with the clinical features of disease. Likewise, the association with the sCD28 and the genotypes of -372 A/G polymorphism was not significant. The polymorphisms of the proximal promoter of CD28 are not associated with SLE, and the polymorphism -372 A/G is not associated with the diagnostic criteria of SLE or the sCD28.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21544637     DOI: 10.1007/s00296-011-1942-7

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  10 in total

1.  Transcriptional regulation of CD28 expression by CD28GR, a novel promoter element located in exon 1 of the CD28 gene.

Authors:  C J Lin; R C Tam
Journal:  J Immunol       Date:  2001-05-15       Impact factor: 5.422

2.  A simple salting out procedure for extracting DNA from human nucleated cells.

Authors:  S A Miller; D D Dykes; H F Polesky
Journal:  Nucleic Acids Res       Date:  1988-02-11       Impact factor: 16.971

3.  Increased CD28 serum levels are not associated with specific clinical activity in systemic lupus erythematosus.

Authors:  Aniel J L Brambila-Tapia; Jorge I Gámez-Nava; Mario Salazar-Páramo; José F Munoz-Valle; Laura González-López; Mara A Llamas-Covarrubias; Sergio R Gutiérrez-Urena; Mónica Vázquez-Del Mercado; Ingrid P Dávalos-Rodríguez
Journal:  Rheumatol Int       Date:  2011-10       Impact factor: 2.631

4.  Preferential elimination of CD28+ T cells in systemic lupus erythematosus (SLE) and the relation with activation-induced apoptosis.

Authors:  H Kaneko; K Saito; H Hashimoto; H Yagita; K Okumura; M Azuma
Journal:  Clin Exp Immunol       Date:  1996-11       Impact factor: 4.330

5.  Aberrant production of soluble costimulatory molecules CTLA-4, CD28, CD80 and CD86 in patients with systemic lupus erythematosus.

Authors:  C K Wong; L C W Lit; L S Tam; E K Li; C W K Lam
Journal:  Rheumatology (Oxford)       Date:  2005-05-03       Impact factor: 7.580

6.  Detection of circulating soluble CD28 in patients with systemic lupus erythematosus, primary Sjögren's syndrome and systemic sclerosis.

Authors:  M Hebbar; P Jeannin; G Magistrelli; P-Y Hatron; E Hachulla; B Devulder; J-Y Bonnefoy; Y Delneste
Journal:  Clin Exp Immunol       Date:  2004-05       Impact factor: 4.330

7.  Association of common T cell activation gene polymorphisms with multiple sclerosis in Australian patients.

Authors:  Suzy M Teutsch; David R Booth; Bruce H Bennetts; Robert N S Heard; Graeme J Stewart
Journal:  J Neuroimmunol       Date:  2004-03       Impact factor: 3.478

8.  Association of polymorphisms in complement component C3 gene with susceptibility to systemic lupus erythematosus.

Authors:  H Miyagawa; M Yamai; D Sakaguchi; C Kiyohara; H Tsukamoto; Y Kimoto; T Nakamura; J-H Lee; C-Y Tsai; B-L Chiang; T Shimoda; M Harada; T Tahira; K Hayashi; T Horiuchi
Journal:  Rheumatology (Oxford)       Date:  2008-01-03       Impact factor: 7.580

9.  Testing clinical criteria for systemic lupus erythematosus in other connective tissue disorders.

Authors:  P L Tan; G B Borman; R D Wigley
Journal:  Rheumatol Int       Date:  1981       Impact factor: 2.631

10.  Effect of CD28 antibody on T cells from patients with systemic lupus erythematosus.

Authors:  C Alvarado; J Alcocer-Varela; L Llorente; Y Richaud-Patin; M Cerbon; D Alarcon-Segovia
Journal:  J Autoimmun       Date:  1994-12       Impact factor: 7.094

  10 in total
  3 in total

1.  Expression profiles of Th17 pathway related genes in human systemic lupus erythematosus.

Authors:  Hai-Feng Pan; Rui-Xue Leng; Chen-Chen Feng; Xiang-Pei Li; Gui-Mei Chen; Bao-Zhu Li; Wang-Dong Xu; Song Guo Zheng; Dong-Qing Ye
Journal:  Mol Biol Rep       Date:  2012-10-09       Impact factor: 2.316

2.  Association of CD28 and CTLA4 haplotypes with susceptibility to primary Sjögren's syndrome in Mexican population.

Authors:  Erika Fabiola López-Villalobos; Francisco Josué Carrillo-Ballesteros; José Francisco Muñoz-Valle; Claudia Azucena Palafox-Sánchez; Yeminia Valle; Gerardo Orozco-Barocio; Edith Oregon-Romero
Journal:  J Clin Lab Anal       Date:  2018-07-10       Impact factor: 2.352

3.  Analysis of the transcriptional networks underpinning the activation of murine macrophages by inflammatory mediators.

Authors:  Sobia Raza; Mark W Barnett; Zohar Barnett-Itzhaki; Ido Amit; David A Hume; Tom C Freeman
Journal:  J Leukoc Biol       Date:  2014-04-10       Impact factor: 6.011

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.